| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.M302458200 |
| P698 | PubMed publication ID | 12700230 |
| P50 | author | Alan Fersht | Q537479 |
| Dmitry B Veprintsev | Q42290924 | ||
| Lars O. Hansson | Q57779013 | ||
| P2093 | author name string | Assaf Friedler | |
| Dmitry B. Veprintsev | |||
| P2860 | cites work | A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | Q24530763 |
| Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. | Q24533476 | ||
| Thermodynamic stability of wild-type and mutant p53 core domain | Q24648879 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Rescuing the function of mutant p53. | Q30329984 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Regulation and function of the p53 tumor suppressor protein | Q34245385 | ||
| Multiple roles of the tumor suppressor p53. | Q34493866 | ||
| Therapeutic exploitation of the p53 pathway | Q34583882 | ||
| Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations | Q40386946 | ||
| Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy | Q40774297 | ||
| Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain | Q44324248 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 24108-24112 | |
| P577 | publication date | 2003-04-16 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Kinetic Instability of p53 Core Domain Mutants | |
| P478 | volume | 278 |
| Q54654711 | 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. |
| Q41484212 | A novel function for p53: regulation of growth cone motility through interaction with Rho kinase |
| Q34333807 | A novel p53 phosphorylation site within the MDM2 ubiquitination signal: II. a model in which phosphorylation at SER269 induces a mutant conformation to p53 |
| Q34490695 | A single-molecule characterization of p53 search on DNA |
| Q38934098 | Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease? |
| Q33842205 | Altered native stability is the dominant basis for susceptibility of α1-antitrypsin mutants to polymerization |
| Q52558518 | Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines. |
| Q51564147 | Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. |
| Q35946185 | Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. |
| Q48262142 | Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain. |
| Q36049159 | Distinct transcriptional responses elicited by unfolded nuclear or cytoplasmic protein in mammalian cells |
| Q45023386 | Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach |
| Q39809467 | Effects of stability on the biological function of p53. |
| Q36492803 | Evaluating Drosophila p53 as a model system for studying cancer mutations |
| Q38134099 | Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor |
| Q36547790 | Exploiting the p53 pathway for the diagnosis and therapy of human cancer. |
| Q43043487 | Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature |
| Q41468886 | Folding of a cyclin box: linking multitarget binding to marginal stability, oligomerization, and aggregation of the retinoblastoma tumor suppressor AB pocket domain |
| Q37808312 | From peptides to proteins: lessons from my years at the Centre for Protein Engineering |
| Q33232877 | Genetic selection for protein solubility enabled by the folding quality control feature of the twin-arginine translocation pathway |
| Q27678152 | Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53 |
| Q28553055 | Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design |
| Q44483891 | Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry |
| Q27667399 | Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer |
| Q64072077 | Interactions of p53 with poly(ADP-ribose) and DNA induce distinct changes in protein structure as revealed by ATR-FTIR spectroscopy |
| Q36187316 | Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition |
| Q92740620 | Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains |
| Q35134797 | Mechanism of initiation of aggregation of p53 revealed by Φ-value analysis |
| Q30400158 | Meet me halfway: when genomics meets structural bioinformatics |
| Q30374671 | Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. |
| Q42088517 | Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations |
| Q40002181 | Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature |
| Q41677793 | Multisite aggregation of p53 and implications for drug rescue |
| Q24791476 | Mutant p53 proteins bind DNA in a DNA structure-selective mode |
| Q57950380 | Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights |
| Q42036836 | Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases |
| Q33354935 | Prediction by graph theoretic measures of structural effects in proteins arising from non-synonymous single nucleotide polymorphisms |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q37088668 | Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide |
| Q46136957 | Rescuing proteins of low kinetic stability by chaperones and natural ligands phenylketonuria, a case study |
| Q36733743 | Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q30951237 | Reversible aggregation plays a crucial role on the folding landscape of p53 core domain |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q33795918 | SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 |
| Q64231035 | Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket |
| Q41768808 | Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53 |
| Q31031898 | Solution structure of p53 core domain: structural basis for its instability |
| Q27655864 | Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core |
| Q34462386 | Stability of p53 homologs |
| Q41453979 | Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding |
| Q37597886 | Structural and functional constraints in the evolution of protein families |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q90443964 | TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database |
| Q27651295 | Targeted rescue of a destabilized mutant of p53 by an in silico screened drug |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q41891513 | The genomics of lung adenocarcinoma: opportunities for targeted therapies |
| Q37808944 | The missing Zinc: p53 misfolding and cancer |
| Q39857411 | The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q37318326 | Ultraslow oligomerization equilibria of p53 and its implications |
| Q36876885 | Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer |
| Q51185198 | Using model proteins to quantify the effects of pathogenic mutations in Ig-like proteins. |
| Q41695683 | Vermont: a multi-perspective visual interactive platform for mutational analysis |
| Q28485288 | Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53 |
Search more.